Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications.
Cancers (Basel)
December 2024
Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Acute promyelocytic leukemia (APL) is a rare type of AML, characterized by the t(15;17) translocation and accounting for 8-15% of cases. The introduction of target therapies, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), radically changed the management of APL, making it the most curable AML subtype. However, a small percentage (estimated to be 2%) of AML presenting with APL-like morphology and/or immunophenotype lacks t(15;17).
View Article and Find Full Text PDFArticle Synopsis
- Chronic myeloid leukemia (CML) can develop from a chronic phase to a rare megakaryoblastic phase, which has a poor prognosis and resistance to standard treatments like tyrosine kinase inhibitors (TKIs).
- A case study details a 39-year-old woman whose CML progressed to this rare phase despite receiving chemotherapy, leading to her death within a month.
- The diagnosis included various tests showing that the disease transformed into acute megakaryoblastic leukemia (AMKL), emphasizing the importance of using megakaryocytic markers in diagnosis for better treatment outcomes.
Massive Bone Marrow Infiltration by Disseminated Alveolar Rhabdomyosarcoma Mimicking Acute Leukemia.
J Pediatr Hematol Oncol
October 2024
Division of Paediatric Hematology-Oncology, University of Bari, Bari.
RMS is a malignant tumor of soft tissues affecting primarily children and adolescents. Around 6% to 23% RMS patients present bone marrow infiltration but leukemia-like involvement is very rare; in these patients cytomorphology on bone marrow smears can lead to misdiagnosis. Differential diagnosis with alveolar RMS should be kept in mind in every pediatric patient presenting with a marked bone marrow involvement in the absence of typical lymphoproliferative findings.
View Article and Find Full Text PDFRecommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.
Cancers (Basel)
June 2024
Hématologie Biologique, Structure Fédérative D'oncogénétique Cyto-Moléculaire du CHU de Caen (SF-MOCAE), CHU de Caen, 14000 Caen, France.
Article Synopsis
- Hairy-cell leukemia (HCL) is a rare blood cancer that has improved prognosis due to treatments like purine nucleoside analogs, but some patients experience relapses and chemotherapy resistance.
- Recent advances in understanding HCL's genetic and cellular mechanisms have led to the development of targeted therapies, including BRAF and MEK inhibitors.
- Updated guidelines emphasize the importance of BRAF mutation for diagnosis, the relevance of certain immunoglobulin mutations for prognosis, and recommend strategies for managing both HCL and similar disorders.
Background: The aim of the study was to improve the clinical cognition of leukemia-like reaction caused by voriconazole and granulocyte colony-stimulating factor and to avoid misdiagnosis or delayed diagnosis.
Methods: A case of drug analysis of Voriconazole combined with granulocyte colony stimulating factor was retrospectively analyzed and related literature was reviewed.
Results: Blood routine of the patient on July 29: WBC 13.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!